Engineering of RNase P Ribozymes for Therapy against Human Cytomegalovirus Infection
Viruses · 2024
DOI: 10.3390/v16081196 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2024. Verfasst von Adam Smith und 3 weiteren Autor:innen. Beteiligte Einrichtung: Program in Comparative Biochemistry, University of California, Berkeley, CA 94720, USA. Hauptthemen laut MEDLINE: Ribonuclease P, Cytomegalovirus, RNA, Catalytic, Cytomegalovirus Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of California at Berkeley.
Abstract (Originalsprache)
Nucleic acid-based gene interference and editing strategies, such as antisense oligonucleotides, ribozymes, RNA interference (RNAi), and CRISPR/Cas9 coupled with guide RNAs, are exciting research tools and show great promise for clinical applications in treating various illnesses. RNase P ribozymes have been engineered for therapeutic applications against human viruses such as human cytomegalovirus (HCMV). M1 ribozyme, the catalytic RNA subunit of RNase P from Escherichia coli, can be converted into a sequence-specific endonuclease, M1GS ribozyme, which is capable of hydrolyzing an mRNA target base-pairing with the guide sequence. M1GS RNAs have been shown to hydrolyze essential HCMV mRNAs and block viral progeny production in virus-infected cell cultures. Furthermore, RNase P ribozyme variants with enhanced hydrolyzing activity can be generated by employing in vitro selection procedures and exhibit better ability in suppressing HCMV gene expression and replication in cultured cells. Additional studies have also examined the antiviral activity of RNase P ribozymes in mice in vivo. Using cytomegalovirus infection as an example, this review summarizes the principles underlying RNase P ribozyme-mediated gene inactivation, presents recent progress in engineering RNase P ribozymes for applications in vitro and in mice, and discusses the prospects of using M1GS technology for therapeutic applications against HCMV as well as other pathogenic viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Program in Comparative Biochemistry, University of California, Berkeley, CA 94720, USA.
- School of Public Health, University of California, Berkeley, CA 94720, USA.
Förderung
- University of California at Berkeley
Zitieren
APA
Smith, A., Zhang, I., Trang, P., & Liu, F. (2024). Engineering of RNase P Ribozymes for Therapy against Human Cytomegalovirus Infection. Viruses. https://doi.org/10.3390/v16081196
Vancouver
Smith A, Zhang I, Trang P, Liu F. Engineering of RNase P Ribozymes for Therapy against Human Cytomegalovirus Infection. Viruses. 2024. doi:10.3390/v16081196
BibTeX
@article{Smith2024,
author = {Smith, Adam and Zhang, Isadora and Trang, Phong and Liu, Fenyong},
title = {Engineering of RNase P Ribozymes for Therapy against Human Cytomegalovirus Infection},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16081196}
}
EUVIMED